New plant in Xiantao built by Wuhan Kernel Biotech, China’s leading manufacturer of Bacillus, capacity increases 1.6 times

On 5th Mar. 2021, Wuhan Kernel Bio-tech Co., Ltd. (hereafter as Kernel Biotech) held the inauguration celebration of Xiantao plant (phase I). The plant covers an area of 200 mu (15 mu equal to 1 hectare), of which 80 mu will be used for phase I, containing four 120-ton fermenters and related downstream facilities. Two production lines had been well installed in phase I, one is for production of Bacillus such as Bacillus thuringiensis and Bacillus subtilis, and the other is for production of antibiotics such as Validamycin. The capacity of the new plant is 1.6 times higher than the plant in Wuhan.

On 5th Mar. 2021, Wuhan Kernel Bio-tech Co., Ltd. (hereafter as Kernel Biotech) held the inauguration celebration of Xiantao plant (phase I). The plant covers an area of 200 mu (15 mu equal to 1 hectare), of which 80 mu will be used for phase I, containing four 120-ton fermenters and related downstream facilities. Two production lines had been well installed in phase I, one is for production of Bacillus such as Bacillus thuringiensis and Bacillus subtilis, and the other is for production of antibiotics such as Validamycin. The capacity of the new plant is 1.6 times higher than the plant in Wuhan.

Li Qing (General Manager of Kernel Biotech) said that green development and agricultural transformation will inevitably happen. Kernel Biotech is currently making use of opportunities for industry development to increase its domestic and international markets in parallel, at a current growth rate of 20% to 30%. (Agropages)

Sign Up For Our E-Newsletter